Begoña Bermejo

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Can...

Clinical cancer research : an official journal of the American Association for Cancer Research · 2 maart 2026

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA...

Clinical cancer research : an official journal of the American Association for Cancer Research · 2 september 2025

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Thera...

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2024

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Tri...

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 november 2024

Driejaars IDFS met PET-gestuurde de-escalatie bij HER2-positief mammacarcinoom: PHERGain driejaars

Lancet (London, England) · 27 april 2024

CCNE1 en PLK1 als mediators van palbociclib-resistentie bij HR+/HER2- mammacarcinoom

Clinical cancer research : an official journal of the American Association for Cancer Research · 14 april 2023

Adjuvante endocriene therapie bij premenopauzaal mammacarcinoom: SOFT twaalfjaars definitief

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 maart 2023

OS met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom: Young-PEARL update

European journal of cancer (Oxford, England : 1990) · 2022-06

AKT-signalering en biomarkers bij neoadjuvant ipatasertib bij TNBC: FAIRLANE analyse

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 maart 2022

21-genen assay en chemotherapievoordeel bij klierpositief mammacarcinoom: RxPONDER fase III

The New England journal of medicine · 16 december 2021

QoL met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom

European journal of cancer (Oxford, England : 1990) · 2021-10

Chemotherapie-de-escalatie gestuurd door PET-respons bij HER2-positief mammacarcinoom: PHERGain fase II

The Lancet. Oncology · 2021-06

Palbociclib plus trastuzumab bij HER2-positief gevorderd mammacarcinoom: SOLTI-1303 PATRICIA fase II

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2020

Nab-paclitaxel versus paclitaxel gevolgd door anthracycline bij HER2-negatief mammacarcinoom: GeparSepto

JAMA oncology · 1 maart 2018

Neoadjuvant buparlisib plus trastuzumab-paclitaxel bij HER2-positief mammacarcinoom: gerandomiseerde fase II

European journal of cancer (Oxford, England : 1990) · 2017-11

18F-fluoromisonidazole PET en neoadjuvante nintedanib bij vroeg HER2-negatief mammacarcinoom: window-of-opportunity studie

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 maart 2017